MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Eli Lilly and Company Revenue 2011-2026 | LLY
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 65.2 B | 45 B | 34.1 B | 28.5 B | 28.3 B | 24.5 B | 22.3 B | 24.6 B | 22.9 B | 21.2 B | 20 B | 19.6 B | 23.1 B | 22.6 B | 24.3 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 65.2 B | 19.6 B | 28.4 B |
Quarterly Revenue Eli Lilly and Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.6 B | 12.7 B | 11.4 B | 11.3 B | 8.77 B | 9.5 B | 8.31 B | 6.96 B | - | 6.94 B | 6.49 B | 7.81 B | - | 6.77 B | 6.74 B | 6.81 B | - | 5.74 B | 5.5 B | 5.86 B | 6.11 B | 5.48 B | 5.64 B | 5.09 B | 5.64 B | 5.31 B | 5.58 B | 4.96 B | 5.41 B | 4.96 B | 5.09 B | 4.51 B | 5.76 B | 5.19 B | 5.4 B | 4.87 B | 5.38 B | 4.96 B | 4.98 B | 4.64 B | 5.12 B | 4.88 B | 4.94 B | 4.68 B | 5.81 B | 5.77 B | 5.93 B | 5.6 B | 5.96 B | 5.44 B | 5.6 B | 5.6 B | - | 6.15 B | 6.25 B | 5.84 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.6 B | 4.51 B | 6.38 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Ultragenyx Pharmaceutical
RARE
|
673 M | $ 19.23 | -3.85 % | $ 1.9 B |  USA |
 |
RedHill Biopharma Ltd.
RDHL
|
8.04 M | $ 0.8 | 0.89 % | $ 428 M |  Israel |
 |
Dr. Reddy's Laboratories Limited
RDY
|
190 B | $ 13.56 | -1.56 % | $ 2.25 B |  India |
 |
Regeneron Pharmaceuticals
REGN
|
14.3 B | $ 742.02 | -1.94 % | $ 77.6 B | USA |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
REGENXBIO
RGNX
|
170 M | $ 7.88 | -4.6 % | $ 406 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
54 K | - | -6.81 % | $ 3.04 B | USA |
 |
Rigel Pharmaceuticals
RIGL
|
294 M | $ 26.2 | -0.64 % | $ 471 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | Israel |
 |
Avidity Biosciences
RNA
|
18.8 M | $ 13.09 | -0.08 % | $ 1.8 B | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
29.5 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
140 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
190 M | $ 78.52 | -4.13 % | $ 5.1 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
277 M | $ 12.57 | -9.96 % | $ 1.91 B | USA |
 |
BeiGene, Ltd.
BGNE
|
5.34 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
SIGA Technologies
SIGA
|
94.6 M | $ 5.35 | 7.76 % | $ 383 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
3.71 B | $ 321.71 | -1.96 % | $ 42.1 B | USA |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
21 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
32.2 M | - | - | $ 3.74 B | USA |
 |
Silence Therapeutics plc
SLN
|
5.3 M | $ 4.8 | -9.6 % | $ 622 M | Britain |
 |
Enochian Biosciences
ENOB
|
42.8 K | - | - | $ 40.5 M | USA |